Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 14/2015

01-09-2015 | Adis Drug Evaluation

Perampanel: A Review in Drug-Resistant Epilepsy

Author: James E. Frampton

Published in: Drugs | Issue 14/2015

Login to get access

Abstract

Perampanel (Fycompa®), an orally-active, selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist, is a first-in-class antiepileptic drug (AED) offering the convenience of once-daily administration. In the EU and US, perampanel is approved in patients with epilepsy aged ≥12 years for the adjunctive treatment of primary generalized tonic-clonic seizures (GTCS) and partial-onset seizures (POS; with or without secondary generalization). In phase III trials of 17 or 19 weeks’ duration, add-on perampanel ≤12 mg/day significantly improved seizure control in patients aged ≥12 years who were experiencing either primary GTCS or POS (with or without secondary generalization), despite ongoing treatment with stable dosages of one to three AEDs. Improvements in seizure control were maintained for up to 2 years in extensions of these core studies. Perampanel also provided sustained seizure control for up to ≈4 years in an extension of two phase II studies in patients aged ≥18 years with drug-resistant POS. Adjunctive perampanel therapy was generally well tolerated. Treatment-emergent adverse events were most commonly CNS-related (e.g. dizziness, somnolence, fatigue and irritability) and dose-related; however, most were of mild to moderate intensity. Clinical experience with perampanel is accumulating, although comparative studies and pharmacoeconomic data that could assist in positioning it relative to other AEDS that are approved and/or recommended as adjunctive therapy are lacking. Nonetheless, on the basis of its overall clinical profile and unique mechanism of action, perampanel is a useful additional adjunctive treatment option for patients with drug-resistant POS, with or without secondary generalization, and primary GTCS.
Literature
1.
Plosker GL. Perampanel: as adjunctive therapy in patients with partial-onset seizures. CNS Drugs. 2012;26(12):1085–96.CrossRefPubMed
2.
Hanada T. The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence. J Receptor Ligand Channel Res. 2014;7:39–50.CrossRef
3.
Hsu WW, Sing CW, He Y, et al. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs. 2013;27(10):817–27.PubMedCentralCrossRefPubMed
4.
Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia. 1981;22:489–501.
5.
6.
7.
Rheims S, Ryvlin P. Pharmacotherapy for tonic-clonic seizures. Expert Opin Pharmacother. 2014;15(10):1417–26.CrossRefPubMed
8.
9.
St. Louis EK, Rosenfeld WE, Bramley T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr Neuropharmacol. 2009;7(2):77–82.
10.
11.
Hanada T. The discovery and development of perampanel for the treatment of epilepsy. Expert Opin Drug Discov. 2014;9(4):449–58.CrossRefPubMed
12.
Steinhoff BJ. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord. 2015;8(3):137–47.PubMedCentralCrossRefPubMed
13.
Eisai Europe Ltd. Fycompa 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg film-coated tablets. EU summary of product characteristics. 2015. http://​ec.​europa.​eu. Accessed 2 July 2015.
14.
15.
Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand. 2013;127(Suppl 197):19–24.CrossRef
16.
Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.CrossRefPubMed
17.
18.
French J, Krauss G, Wechsler R, et al. Adjunctive perampanel (PER) for treatment of drug-resistant primary generalized tonic-clonic (PGTC) seizures in patients (PTS) with idiopathic generalized epilepsy (IGE): a double-blind, randomized, placebo-controlled phase III trial (abstract 2.389 plus poster). In: 68th American Epilepsy Society Annual Meeting. 2014.
19.
French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589–96.PubMedCentralCrossRefPubMed
20.
French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54(1):117–25.CrossRefPubMed
21.
Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408–15.CrossRefPubMed
22.
Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481–9.CrossRefPubMed
23.
Steinhoff BJ, O’Brien TJ, Yang H, et al. Efficacy of adjunctive perampanel in idiopathic generalised epilepsy patients with drug-resistant primary generalised tonic-clonic seizures by age, sex, race: a double-blind PBO-controlled phase 3 trial [abstract no. O2112]. Eur J Neurol. 2015;22(Suppl 1):64.
24.
Krauss GL, Perucca E, Ben-Menachem E, et al. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307. Epilepsia. 2014;55(7):1058–68.PubMedCentralCrossRefPubMed
25.
Gidal B, Laurenza A, Hussein Z, et al. Permapanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1972–80.PubMedCentralCrossRefPubMed
26.
Tsong W, Hudgens S, Forsythe A, et al. Impact of adding perampanel to existing anti-epileptic drug (AED) therapy on health-related quality of life (HRQL) as measured by the quality of life in epilepsy inventory (QOLIE-31-P) in a pooled population of patients with partial-onset seizures (POS) from 3 phase III trials (abstract no. 3.301). In: 68th American Epilepsy Society Annual Meeting. 2014.
27.
Rosenfeld WE, Conry J, Lagae L, et al. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. Eur J Paediatr Neurol. 2015;19:435–45.CrossRefPubMed
28.
Leppik I, Wechsler R, Williams B, et al. Efficacy and safety of perampanel in the subgroup of elderly patients included in the phase III epilepsy clinical trials. Epilepsy Res. 2015;110:216–20.CrossRefPubMed
29.
Vazquez B, Yang H, Williams B, et al. Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia. 2015;56(7):e90–4.CrossRefPubMed
30.
Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies. Epilepsia. 2014;55(3):423–31.CrossRefPubMed
31.
Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263–9.PubMed
32.
Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125:8–15.CrossRefPubMed
33.
34.
Gidal BE, Ferry J, Majid O. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54(8):1490–7.CrossRefPubMed
35.
Rugg-Gunn F. Adverse effects and safety profile of perampanel: a review of pooled data. Epilepsia. 2014;55(Suppl 1):13–5.CrossRefPubMed
36.
Glauser T, Laurenza A, Yang H, et al. Efficacy and safety of adjunctive perampanel based on number of antiepileptic drugs at baseline [abstract no. P3.273]. Neurology. 82(10 Suppl).
37.
Ko D, Yang H, Williams B, et al. Perampanel in the treatment of partial seizures: time to onset and duration of most common adverse events from pooled phase III and extension studies. Epilepsy Behav. 2015;48:45–52.CrossRefPubMed
38.
Ettinger AB, LoPresti A, Yang H, et al. Psychiatric and behavioural adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56(8):1252–63.CrossRefPubMed
39.
Leppik I, Yang H, Williams B, et al. Analysis of falls in epilepsy patients with partial onset seizures in perampanel phase 3 trials [abstract no. P3.272]. Neurology. 2014;82(10 Suppl).
40.
Ettinger AB, Dobrinsky C, Yang H, et al. Review of suicidality events in perampanel clinical studies [poster no. 2.276]. In: 68th American Epilepsy Society Annual Meeting. 2014.
41.
Yang H, Laurenza A, Williams B, et al. Lack of effect of perampanel on QT interval duration: results from a thorough QT analysis and pooled partial seizure phase III clinical trials. Epilepsy Res. 2015;114:122–30.CrossRefPubMed
42.
Laurenza A, Yang H, Squillacote D, et al. Adjunctive perampanel does not increase the risk of cardiac adverse events compared with placebo: a pooled analysis of three phase III trials [abstract no. P204]. Epilepsia. 2013;54(Suppl 3):70.
43.
Ben-Menachem E. Medical management of refractory epilepsy—practical treatment with novel antiepileptic drugs. Epilepsia. 2014;55(Suppl 1):3–8.CrossRefPubMed
44.
Trinka E. Ideal characteristics of an antiepileptic drug: how do these impact treatment decisions for individual patients? Acta Neurol Scand. 2012;126(Suppl 194):10–8.CrossRef
45.
French J, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;62:1261–73.CrossRefPubMed
46.
Loscher W, Klitgaard H, Twyman RE, et al. New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.CrossRefPubMed
47.
Meador K, Yang H, Williams B, et al. Effect of adjunctive perampanel on cognition in adolescents with inadequately controlled partial-onset seizures [poster no. P4.344]. In: 66th American Academy of Neurology Annual Meeting. 2014.
48.
49.
Thigpen J, Miller SE, Pond BB, et al. Behavioural side effects of antiepileptic drugs. US Pharm. 2013;38(11):HS15–20.
50.
Mula M, Hesdorffer DC. Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. Drug Health Patient Saf. 2011;3:15–20.
51.
Siamouli M, Samara M, Fountoulakis KN, et al. Is antiepileptic-induced suicidality a data-based class effect or an exaggeration? A comment on the literature. Harv Rev Psychiatry. 2014;22(6):379–81.CrossRefPubMed
52.
Hemery C, Ryvlin P, Rheims S. Prevention of generalized tonic-clonic seizures in refractory focal epilepsy: a meta-analysis. Epilepsia. 2014;55(11):1789–99.CrossRefPubMed
53.
54.
Biro A, Stephani U, Tarallo T, et al. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences. Neuropediatrics. 2015;46(2):110–6.CrossRefPubMed
Metadata
Title
Perampanel: A Review in Drug-Resistant Epilepsy
Author
James E. Frampton
Publication date
01-09-2015
Publisher
Springer International Publishing
Published in
Drugs / Issue 14/2015
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-015-0465-z

Other articles of this Issue 14/2015

Drugs 14/2015 Go to the issue

AdisInsight Report

Alirocumab: First Global Approval

Adis Drug Evaluation

AFREZZA® (insulin human) Inhalation Powder: A Review in Diabetes Mellitus

AdisInsight Report

Brexpiprazole: First Global Approval

Review Article

Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities

Review Article

Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics

Review Article

Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents